FDA approves new bispecific antibody for blood cancer treatment.
The FDA has approved AbbVie and Genmab's blood cancer therapy, Epkinly, for adult patients who have received at least two prior lines of treatment. The therapy treats a type of advanced large B-cell lymphoma and is the first-of-its-kind to be approved by the FDA for the disease. The list price of Epkinly is $37,500 per month, and it is expected to reach $2.75 billion in peak sales globally. The therapy is being co-developed by AbbVie and Genmab as part of a $750 million deal made in 2020 to jointly develop and commercialize three of Genmab's cancer-targeting antibody products.